
The first human trials of an Ebola vaccine will begin in the United States next week, officials said Thursday, after the World Health Organization (WHO) warned that more than 20,000 people could end up being infected before the outbreak in West Africa can be stopped, dpa reported.
The American National Institutes of Health (NIH) said it will sponsor the first trial of the vaccine, which it co-developed with drug manufacturer GlaxoSmithKline, at its clinical centre in Bethesda, Maryland. Other test sites will include Britain and potentially Gambia, Mali and Nigeria.
The trial is being fast-tracked as the Ebola outbreak continues to gather pace in West Africa, with the death toll in the region now at 1,552, according to the WHO.
The Geneva-based organization said 3,069 suspected or confirmed cases had been reported in Guinea, Liberia, Nigeria and Sierra Leone.
However, the WHO estimates the actual number of cases may be two to four times higher than currently reported.
More than 40 per cent of all cases occurred within the past three weeks, pointing to an acceleration of the infection rates in the region, WHO said.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor